Sophie de Carné Trécesson

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 7

Top Venues

Cancer research

Nature communications

The Francis Crick Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The Francis Crick Institute Nov 03 2014

United Kingdom

Postdoc :: Oncogene Biology Laboratory

Publications

Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer. Cancer research (2024)
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer research 84 (14) (2024)
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer research 84 (14) (2024)
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer research 84 (14) (2024)
Jesse Boumelha, Sophie de Carné Trécesson, Emily K Law, Pablo Romero-Clavijo, Matthew A Coelho, Kevin W Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R Caswell, Miguel Murillo, David C Hancock, Prokopios P Argyris, William L Brown, Cameron Durfee, Lindsay K Larson, Rachel Isaksson Vogel, Alejandro Suarez-Bonnet, Simon Lawrence Priestnall, Philip East, Sarah J Ross, George Kassiotis, Miriam Molina-Arcas, Charles Swanton, Reuben Stewart Harris, Julian Downward
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations. Cancer research 82 (19) (2022)
Philip East, Gavin P Kelly, Dhruva Biswas, Michela Marani, David C Hancock, Todd Creasy, Kris Sachsenmeier, Charles Swanton, null null, Julian Downward, Sophie de Carné Trécesson
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma. Nature communications 13 (1) (2022)
Sophie de Carné Trécesson, Frédérique Souazé, Agnès Basseville, Anne-Charlotte Bernard, Jessie Pécot, Jonathan Lopez, Margaux Bessou, Kristopher A Sarosiek, Anthony Letai, Sophie Barillé-Nion, Isabelle Valo, Olivier Coqueret, Catherine Guette, Mario Campone, Fabien Gautier, Philippe Paul Juin
BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature communications 8 (1) (2017)

Sophie de Carné Trécesson.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sophie de Carné Trécesson